{"prompt": "['59', 'MC1488 WEE1', 'MCCC', 'bacteriostatic agents should not be used for the preparation of either high', 'doses or intrathecal doses of cytarabine.', '15.24', 'Administration: Low-dose cytarabine (LD-AraC) will be administered at a', 'starting dose of 20 mg BID subcutaneously (sc) for 10 days of a 28-day cycle.,', 'with dosing adjustments as outlined in section 8.', '15.25', 'Pharmacokinetic information:', 'Distribution: Vd: Total body water; widely and rapidly since it enters the', 'cells readily; crosses blood-brain barrier with CSF levels of 40% to 50% of', 'plasma level', 'Metabolism: Primarily hepatic; metabolized by deoxycytidine kinase and', 'other nucleotide kinases to aracytidine triphosphate (active); about 86% to', '96% of dose is metabolized to inactive uracil arabinoside.', 'Half-life elimination: I.V.: Initial: 7-20 minutes; Terminal: 1-3 hours.', 'Excretion: Urine (~80%) within 24 hours.', '15.26', 'Potential Drug Interactions:', 'Decreased Effect: Cytarabine may decrease the effect of Flucytosine;', 'cytarabine may decrease digoxin absorption.', '15.27 Known potential adverse events: Consult the package insert for the most', 'current and complete information.', 'Warnings/Precautions: Potent Myelosuppressive agent', 'Common known potential toxicities, frequency not defined:', 'Other: Fever', 'Dermatologic: Rash', 'Gastrointestinal: Anal inflammation, anal ulceration, anorexia, diarrhea,', 'mucositis, nausea, vomiting', 'Hematologic: Myelosuppression, neutropenia, anemia, thrombocytopenia,', 'bleeding, leukopenia, megaloblastosis, reticulocytes decreased', 'Hepatic: Hepatic dysfunction, transaminases increased (acute)', 'Local: Thrombophlebitis', 'Less common known potential toxicities:', 'Cardiovascular: Chest pain, pericarditis', 'Central nervous system: Dizziness, headache, neural toxicity, neuritis', 'Dermatologic: Alopecia, pruritus, skin freckling, skin ulceration, urticaria', 'Gastrointestinal: Abdominal pain, bowel necrosis, esophageal ulceration,', 'esophagitis, pancreatitis, sore throat', 'Genitourinary: Urinary retention', 'Hepatic: Jaundice', 'Local: Injection site cellulitis', 'Ocular: Conjunctivitis', 'Renal: Renal dysfunction', 'Respiratory: Dyspnea', 'Miscellaneous: Allergic edema, anaphylaxis, sepsis', 'Infrequent and/or case reports:', 'Amylase increased, aseptic meningitis, cardiopulmonary arrest (acute),', 'cerebral dysfunction, cytarabine syndrome (bone pain, chest pain,']['60', 'MC1488 WEE1', 'MCCC', 'conjunctivitis, fever, maculopapular rash, malaise, myalgia);', 'exanthematous pustulosis, hyperuricemia, injection site inflammation', '(SubQ injection), injection site pain (SubQ injection), interstitial', 'pneumonitis, lipase increased, paralysis, rhabdomyolysis, veno-occlusive', 'liver disease', '15.28', 'Drug procurement: Commercial supplies. Pharmacies or clinics shall obtain', 'supplies from normal commercial supply chain or wholesaler.', '16.0', 'Statistical Considerations and Methodology', '16.1', 'Overview:', 'This study is a phase II screening study. It is divided into two portions. The safety', 'portion is designed to determine the dose of the treatment agents. The expansion portion', 'is designed to continue enrollment at the acceptable dose levels to determine efficacy of', 'treatment in elderly (age 60+) newly diagnosed AML patients (Arm A: AZD1775 days 1- -', '5 & 8-12) and AraC days 1-5 & 8-12) and to make a selection of one of the two', 'randomized arms for Relapsed/Refractory AML and HMA failure MDS patients (Arm B:', 'AZD1775 days 1-5 & 8-12) and AraC days 1-5 & 8-12; Arm C: AZD1775 days 1-5, 8-', '12, 15-19, 22-26).', 'The purpose of this screening design is NOT TO ensure a high probability that the very', 'best treatment is selected, but to ensure a low probability that a poor treatment is selected.', 'In other words, at the conclusion of this trial, we cannot make a definitive conclusion', 'about the superiority of one treatment compared to the other, but we can ensure that there', 'is a small probability of bringing the inferior treatment forward.', '16.2', 'Statistical Design and Analysis for the Primary Endpoint', '16.21', 'Primary Endpoint', 'The primary endpoint of this trial is the rate of complete response (CR plus CRi).', 'Throughout Section 16.0, complete response will be considered synonymous', 'with \"success\", unless specified otherwise. All patients meeting the eligibility', 'criteria, who have signed a consent form, and have begun treatment at the study', 'MTD will be evaluable for complete response, with the exception of patients who', 'are determined to be a major treatment violation.', 'Treatment Responses will be assessed by standard criteria for the respective disease', 'per NCCN guidelines or according to specific criteria from expert panels (i.e. the', 'International Working Group Criteria for the response in acute myeloid leukemias).', 'Response will be assessed by peripheral blood criteria at the end of each cycle and', 'every other cycle (for MDS) thereafter (Burnett et al. 2007. Gileset al. 2005,', 'Kantarijian et al. 2012, Fenaux et al. 2009).', 'Bone marrow tests to assess responses will be carried as outlined in the study tables', 'Table 4.1 and 4.2.']\n\n###\n\n", "completion": "END"}